Search Results

Displaying Results 4851-4875 of 10951 "'T'"

Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

series is on track to deliver a late lead which meets the dose criteria for prophylaxis, i.e. a single dose <500mg for t>MIC for 7d (minimum) or a single dose <500mg for t>MIC for 28d (ideal). 3. Addressing the hERG inhibition

More news about: GHIT Fund


Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi

series is on track to deliver a late lead which meets the dose criteria for prophylaxis, i.e. a single dose <500mg for t>MIC for 7d (minimum) or a single dose <500mg for t>MIC for 28d (ideal). 3. Addressing the hERG inhibition

More news about: GHIT Fund


Apr 21, 2026, 21:52 ET /C O R R E C T I O N -- Smashify/

More news about: Smashify


Apr 21, 2026, 21:30 ET Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase

More news about: Nektar Therapeutics


Apr 21, 2026, 21:28 ET /C O R R E C T I O N -- Smashify/

More news about: Smashify


Apr 21, 2026, 19:30 ET ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

Mary's Hospital, who served as the principal investigator of the study.VT-EBV-N is an Epstein-Barr virus (EBV)-specific T cell therapy being developed for the treatment of NK/T-cell lymphoma, a rare and aggressive malignancy with a high risk of relapse.According to the company, the Phase 2 study

More news about: ViGenCell Inc.


Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./

More news about: Nuvation Bio Inc.


Apr 21, 2026, 18:11 ET DRVN Investor Alert: Driven Brands Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action Alleging Pervasive Accounting Errors and Internal Control Failures - Hagens Berman

www.youtube.com/watch?v=EwsGKJAAbdM&t=2sIf you'd like more information and answers to additional frequently asked questions about the Driven case and the firm's

More news about: Hagens Berman Sobol Shapiro LLP


Apr 21, 2026, 16:30 ET M&T Bank Corporation Announces Second Quarter Dividends

/PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE:MTB) announced that it has declared a quarterly cash dividend of $1.50 per share on its common stock. The dividend will be payable June 30, 2026, to shareholders of record at the close of business on June 1, 2026.M&T has also declared

More news about: M&T Bank Corporation


Apr 21, 2026, 16:27 ET /C O R R E C T I O N -- Duke Energy/

More news about: Duke Energy


Apr 21, 2026, 16:23 ET BioMarin Announces Board Leadership Transition

Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif., April 21, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that the Board of Directors

More news about: BioMarin Pharmaceutical Inc.


Apr 21, 2026, 16:17 ET /C O R R E C T I O N -- Liberty Service Partners/

/C O R R E C T I O N – Liberty Service Partners/ In the news release, Liberty Service Partners Expands into the Mid-Atlantic with Partnership with HVAC & Plumbing Unlimited, issued 21-Apr-2026 by Liberty Service Partners over PR Newswire, we are advised by the company that changes have been

More news about: Liberty Service Partners


Apr 21, 2026, 16:05 ET Resideo To Release First Quarter 2026 Financial Results on May 12, 2026

Media:Christopher T. Lee Garrett Terry

More news about: Resideo Technologies, Inc.


Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)

Elimova E, Rha SY, Shitara K, Liu T,Tabernero J, Lee KW, Schenker M,Tebbutt NC, Ajani JA, Salimin N, Ku GY,Kim JG, Diaz IA, Zhang J, Pietrantonio F,Bai

More news about: Jazz Pharmaceuticals plc


Apr 21, 2026, 16:00 ET Health In Tech to Present at the Market Movers Investor Summit

[email protected] Equity Group Kalle Ahl, CFA          T: (303) 953-9878      [email protected]

More news about: Health In Tech Inc.


Apr 21, 2026, 15:40 ET /C O R R E C T I O N -- Harrell-Fish, LLC/

More news about: Harrell-Fish, LLC


Apr 21, 2026, 13:29 ET /C O R R E C T I O N -- Drivestream/

More news about: Drivestream


Apr 21, 2026, 13:14 ET Fastmarkets et Expana forment un partenariat stratégique pour renforcer l'information sur le marché des produits forestiers

idéaux pour nos clients, et ce partenariat représente une étape importante dans l'élargissement des informations disponibles sur notre plateforme », a-t-elle ajouté.Expana fournit des informations et des analyses de marché complètes sur les chaînes d'approvisionnement des produits alimentaires,

More news about: Fastmarkets Global Limited


Apr 21, 2026, 13:06 ET /C O R R E C T I O N -- Espolòn Tequila/

More news about: Espolòn Tequila


Apr 21, 2026, 13:02 ET /C O R R E C T I O N -- Ladder/

More news about: Ladder


Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

including EGFR driver mutations (L858R and exon 19 deletions), resistant double mutations (including T790M/C797S in the context of L858R or exon 19 deletion), and the challenging triple mutations (C797X plus T790M plus L858R or exon 19 deletion).In addition, Dizal will present the latest findings from

More news about: Dizal Pharmaceutical


Apr 21, 2026, 12:03 ET Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy

to drive long-term anti-tumor T cell function without T cell exhaustion. By keeping antigen recognition separate from T cell activation, the multi-chain architecture is intended to sustain T cell activity to provide a more durable response compared to single-chain CAR T approaches.CELESTIAL-301

More news about: Verismo Therapeutics


Apr 21, 2026, 12:00 ET Princess Cruises and Holland America Line Commit Initial Investment to Rebuild Ketchikan American Legion Post Destroyed by Arson

revolutionary Global Fresh Fish Program, put Holland America Line at the forefront of premium cruising.About Joseph T. Craig American Legion Post 3Founded in 1919, Joseph T. Craig American Legion Post 3 in Ketchikan, Alaska, is the state's oldest American Legion post, serving veterans, their

More news about: Princess Cruises


Apr 21, 2026, 11:46 ET /C O R R E C T I O N -- Bybit/

More news about: Bybit


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.